NEW YORK, NY / ACCESSWIRE / March 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Investigation Details:
On February 28, 2024, Inari announced its fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the U.S. Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act concerning certain payments to healthcare professionals. On this news, Inari's stock price fell $12.14 per share, or 20.84%, to close at $46.12 per share on February 29, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Inari securities, you can assist this investigation by visiting the firm's site: bgandg.com/NARI. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on accesswire.com
